Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted EBITDA of $37.3 million for Q1 2026, down 3.28% sequentially from $38.6 million in Q4 2025, and down 33.7% YoY from $56.2 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported EBITDA for 8 years, with the latest figure at $37.3 million in Q1 2026.
- Quarterly EBITDA fell 33.7% year-over-year to $37.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189.5 million (down 2.83% YoY) and the FY2025 annual result came in at $208.5 million, up 9.25% from the prior year.
- EBITDA retreated to $37.3 million in Q1 2026 per HRMY's latest filing, from $38.6 million in the prior quarter.
- Over five years, EBITDA peaked at $65.5 million in Q3 2025 and troughed at $11.9 million in Q3 2022.
- A 5-year average of $44.0 million and a median of $46.9 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA soared 442.05% in 2023, then sank 54.47% in 2024.
- Over 5 years, EBITDA stood at $47.6 million in 2022, then declined by 15.58% to $40.2 million in 2023, then surged by 38.64% to $55.7 million in 2024, then tumbled by 30.81% to $38.6 million in 2025, then declined by 3.28% to $37.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $37.3 million, $38.6 million, and $65.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 89.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.32 Mn |
| Mar 31, 2026 | 37.29 Mn |
| Dec 31, 2025 | 38.56 Mn |
| Sep 30, 2025 | 65.49 Mn |
| Jun 30, 2025 | 48.18 Mn |
| Mar 31, 2025 | 56.25 Mn |
| Dec 31, 2024 | 55.73 Mn |
| Sep 30, 2024 | 61.71 Mn |
| Jun 30, 2024 | 21.36 Mn |
| Mar 31, 2024 | 52.03 Mn |
| Dec 31, 2023 | 40.20 Mn |
| Sep 30, 2023 | 64.51 Mn |
| Jun 30, 2023 | 46.90 Mn |
| Mar 31, 2023 | 40.42 Mn |
| Dec 31, 2022 | 47.61 Mn |
| Sep 30, 2022 | 11.90 Mn |
| Jun 30, 2022 | 33.12 Mn |
| Mar 31, 2022 | 27.56 Mn |
| Dec 31, 2021 | 28.63 Mn |
| Sep 30, 2021 | 21.05 Mn |